Endothelial cell protein C receptor-mediated redistribution and tissue-level accumulation of factor VIIa

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 11, 2012, Pages 2383-2391

  Clark, C A ^a   Vatsyayan, R ^a   Hedner, U ^b   Esmon, C T ^c   Pendurthi, U R ^a   Rao, L V M ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Endothelial cell protein C receptor; Factor VIIa; Hemophilia; Hemostasis; Tissue factor; Transport

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 7A; ENDOTHELIAL PROTEIN C RECEPTOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CIRCULATION; CONTROLLED STUDY; DRUG HALF LIFE; HEMOPHILIA; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; TRANSCYTOSIS; VASCULAR ENDOTHELIUM;

ENDOTHELIAL CELL PROTEIN C RECEPTOR; FACTOR VIIA; HEMOPHILIA; HEMOSTASIS; TISSUE FACTOR; TRANSPORT;

ANIMALS; BIOLOGICAL TRANSPORT; BLOOD COAGULATION FACTORS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FACTOR VIIA; HEMOPHILIA A; HEMOSTASIS; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PROTEIN BINDING; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; THROMBOPLASTIN; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84868159252     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04917.x     Document Type: Article

References (33)

1. Bauer KA, Kass BL, Ten Cate H, Hawiger JJ, Rosenberg RD. Factor IX is activated in vivo by the tissue factor mechanism. Blood 1990; 76: 731-6.
2. Bauer KA, Kass BL, Ten Cate H, Bednarek MA, Hawiger JJ, Rosenberg RD. Detection of factor X activation in humans. Blood 1989; 74: 2007-15.
3. Ten Cate H, Bauer K, Levi M, Edgington TS, Sublett RD, Barzegar S, Kass B, Rosenberg RD. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993; 92: 1207-12.
4. Butenas S, Bouchard BA, Brummel-Ziedins KE, Parhami-Seren B, Mann KG. Tissue factor activity in whole blood. Blood 2005; 105: 2764-70.
5. Hedner U, Ezban M. Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis. Annu Rev Med 2008; 59: 29-41.
6. Saxon BR, Shanks D, Jory CB, Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost 2001; 86: 1126-7.
7. Young G, McDaniel M, Nugent DJ. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia 2005; 11: 203-7.
8. Blatny J, Kohlerova S, Zapletal O, Fiamoli V, Penka M, Smith O. Prophylaxis with recombinant factor VIIa for the management of bleeding episodes during immune tolerance treatment in a boy with severe haemophilia A and high-response inhibitors. Haemophilia 2008; 14: 1140-2.
9. Morfini M, Auerswald G, Kobelt RA, Rivolta GF, Rodriguez-Martorell J, Scaraggi FA, Altisent C, Blatny J, Borel-Derlon A, Rossi V. Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia 2007; 13: 502-7.
10. Tcheng WY, Donkin J, Konzal S, Wong WY. Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency. Haemophilia 2004; 10: 295-8.
11. Mathijssen NC, Masereeuw R, Verbeek K, Lavergne JM, Costa JM, van Heerde WL, Novakova IR. Prophylactic effect of recombinant factor VIIa in factor VII deficient patients. Br J Haematol 2004; 125: 494-9.
12. Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, Serban MA. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
13. Ghosh S, Pendurthi UR, Steinoe A, Esmon CT, Rao LV. Endothelial cell protein C receptor acts as a cellular receptor for factor VIIa on endothelium. J Biol Chem 2007; 282: 11849-57.
14. Preston RJ, Ajzner E, Razzari C, Karageorgi S, Dua S, Dahlback B, Lane DA. Multifunctional specificity of the protein C/activated protein C Gla domain. J Biol Chem 2006; 281: 28850-7.
15. Lopez-Sagaseta J, Montes R, Puy C, Diez N, Fukudome K, Hermida J. Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activity. J Thromb Haemost 2007; 5: 1817-24.
16. Sen P, Gopalakrishnan R, Kothari H, Keshava S, Clark CA, Esmon CT, Pendurthi UR, Rao LV. Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection. Blood 2011; 117: 3199-208.
17. Nayak RC, Sen P, Ghosh S, Gopalakrishnan R, Esmon CT, Pendurthi UR, Rao LVM. Endothelial cell protein C receptor cellular localization and trafficking. Blood 2009; 114: 1974-86.
18. Gopalakrishnan R, Hedner U, Ghosh S, Nayak R, Allen TC, Pendurthi UR, Rao LV. Bio-distribution of pharmacologically administered rFVIIa. J Thromb Haemost 2010; 8: 301-10.
19. Sen P, Clark CA, Gopalakrishnan R, Hedner U, Esmon CT, Pendurthi UR, Rao LVM. Factor VIIa binding to endothelial cell protien C receptor: differences between mouse and human systems. Thromb Haemost 2012; 107: 951-61.
20. Gu JM, Katsuura Y, Ferrell GL, Grammas P, Esmon CT. Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo. Blood 2000; 95: 1687-93.
21. Li W, Zheng X, Gu JM, Ferrell GL, Brady M, Esmon NL, Esmon CT. Extraembryonic expression of EPCR is essential for embryonic viability. Blood 2005; 106: 2716-22.
22. Li W, Zheng X, Gu J, Hunter J, Ferrell GL, Lupu F, Esmon NL, Esmon CT. Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. J Thromb Haemost 2005; 3: 1351-9.
23. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
24. Petersen LC, Elm T, Ezban M, Krogh TN, Karpf DM, Steino A, Olsen EH, Sorensen BB. Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors. Thromb Haemost 2009; 101: 818-26.
25. Gopalakrishnan R, Pendurthi UR, Hedner U, Agerso H, Esmon CT, Rao LV. Influence of endothelial cell protein C receptor on plasma clearance of factor VIIa. J Thromb Haemost 2012; 10: 971-3.
26. Almus FE, Rao LVM, Rapaport SI. Regulation of factor VIIa/tissue factor functional activity in an umbilical vein model. Arterioscler Thromb 1993; 13: 105-11.
27. Almus FE, Rao LVM, Fleck RA, Rapaport SI. Properties of factor VIIa/tissue factor complexes in an umbilical vein model. Blood 1990; 76: 354-60.
28. Hoffman M, Colina CM, McDonald AG, Arepally GM, Pedersen L, Monroe DM. Tissue factor around dermal vessels has bound factor VII in the absence of injury. J Thromb Haemost 2007; 5: 1403-8.
29. Gleeson EM, O'Donnell JS, Preston RJ. The endothelial cell protein C receptor: cell surface conductor of cytoprotective coagulation factor signaling. Cell Mol Life Sci 2012; 69: 717-26.
30. Pendurthi UR, Rao LV. Factor VIIa interaction with endothelial cells and endothelial cell protein C receptor. Thromb Res 2010; 125(Suppl. 1): S19-22.
31. Montes R, Puy C, Molina E, Hermida J. Is EPCR a multi-ligand receptor? Pros and cons. Thromb Haemost 2012; 107: 815-26.
32. Sen P, Ghosh S, Ezban M, Pendurthi UR, Vijaya Mohan RL. Effect of glycoPEGylation on factor VIIa binding and internalization. Haemophilia 2010; 16: 339-48.
33. Karpf DM, Sorensen BB, Hermit MB, Holmberg HL, Tranholm M, Bysted BV, Groth AV, Bjorn SE, Stennicke HR. Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa. Thromb Res 2011; 128: 191-5.